In this Progress article, we highlight recent insights into the role of exosomal PDL1 in immune oncology and how it may be useful as a biomarker for the management of cancer or to define a subset of patients who would benefit from therapeutics that block exosome production....
[0002]外泌体(exosome),是一种能被大多数细胞分泌的微小膜泡,直径大约30-150 nm,具有脂质双层膜结构,能很好地保护其包被的物质。这种微小膜泡中含有宿主细胞来源的特异的蛋白、脂质和核酸,能作为信号分子传递给其他细胞,是细胞之间通讯的重要媒介,可使受体细胞发生多种生物功能的改变。据报道,这种外逸性介导的细胞...
Exosome-transmitted lncARSR promotes Sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–68. Article CAS PubMed Google Scholar Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA ...
DNA损伤反应(DDR)通路的遗传改变是B细胞恶性肿瘤中化学免疫疗法(CIT)耐药的常见机制。之前已经表明,CIT的协同作用依赖于化疗引起的肿瘤细胞和巨噬细胞之间的分泌串扰。然而,恶性细胞中DNA损伤途径的改变如何在功能上影响CIT的复杂相互作用和结果仍有待阐明。近日,来自德国科隆大学医院的研究人员在Blood杂志上发表文章,报道...
PD-L1 (B7–H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Mol Cell. 2019;74:1215–26. https://doi.org/10.1016/j.molcel.2019.04.005. e1214. Article CAS PubMed PubMed Central Google Scholar Marechal,...
In this Progress article, we highlight recent insights into the role of exosomal PDL1 in immune oncology and how it may be useful as a biomarker for the management of cancer or to define a subset of patients who would benefit from therapeutics that block exosome production. 展开 ...
IL-2 therapy induced exosomes with PDL1 (1.4±0.8 vs 0.09±0.14; p<0.01) CD73 (2.3±1.2 vs 0.4±0.3; p<0.01) on day 45, and decreased exosome induction with SAgs (Myosin 0.4±0.2; Vimentin 0.7±0.4) and Abs to SAgs (Myosin 540±283, Vimentin 295±47). Circulating exosomes ...